Search Results for: SRC

Novel Interactant Symbol Name
Associated Pathways
Binding Drugs
Associated Diseases
BCAR1 BCAR1 scaffold protein, Cas family member
  • Downstream signal transduction
  • p130Cas linkage to MAPK signaling for integrins
  • VEGFA-VEGFR2 Pathway
  • VEGFA-VEGFR2 Pathway
  • PTK6 Regulates RHO GTPases, RAS GTPase and MAP kinases
BCCIP BRCA2 and CDKN1A interacting protein
BCR BCR activator of RhoGEF and GTPase
  • Signaling by cytosolic FGFR1 fusion mutants
  • Signaling by FGFR1 in disease
  • RHOA GTPase cycle
  • RHOB GTPase cycle
  • RHOC GTPase cycle
  • CDC42 GTPase cycle
  • RAC1 GTPase cycle
  • RAC2 GTPase cycle
  • RAC3 GTPase cycle
  • Imatinib
  • Dasatinib
  • Bosutinib
  • Ponatinib
  • Acute lymphoblastic leukemia (ALL) (precursor B lymphoblastic leukemia)
  • Chronic myeloid leukemia (CML)
BMX BMX non-receptor tyrosine kinase
  • Apoptotic cleavage of cellular proteins
  • Synthesis of PIPs at the plasma membrane
  • Fostamatinib
  • Zanubrutinib
BRMS1 BRMS1 transcriptional repressor and anoikis regulator
  • HDACs deacetylate histones
  • Potential therapeutics for SARS
CA3 carbonic anhydrase 3
  • Reversible hydration of carbon dioxide
  • Topiramate
  • Ethoxzolamide
  • Sulpiride
  • Celecoxib
  • Benzthiazide
  • Valdecoxib
  • Cyclothiazide
  • Methazolamide
  • Acetazolamide
  • Dorzolamide
  • Zonisamide
  • Diclofenamide
  • Brinzolamide
  • Ellagic acid
  • Saccharin
CASP8 caspase 8
  • Apoptotic cleavage of cellular proteins
  • Caspase activation via Death Receptors in the presence of ligand
  • NOD1/2 Signaling Pathway
  • TRIF-mediated programmed cell death
  • Caspase-mediated cleavage of cytoskeletal proteins
  • Regulation by c-FLIP
  • RIPK1-mediated regulated necrosis
  • CASP8 activity is inhibited
  • TNFR1-induced proapoptotic signaling
  • Regulation of TNFR1 signaling
  • CLEC7A/inflammasome pathway
  • Regulation of necroptotic cell death
  • Dimerization of procaspase-8
  • Activation, myristolyation of BID and translocation to mitochondria
  • Apoptotic execution phase
  • FasL/ CD95L signaling
  • TRAIL signaling
  • TLR3-mediated TICAM1-dependent programmed cell death
  • NF-kB activation through FADD/RIP-1 pathway mediated by caspase-8 and -10
  • Microbial modulation of RIPK1-mediated regulated necrosis
  • Defective RIPK1-mediated regulated necrosis
  • Regulation of NF-kappa B signaling
  • Trichostatin A
  • AN-9
  • Bryostatin 1
  • Bardoxolone
  • Oleandrin
  • Autoimmune lymphoproliferative syndromes (ALPS), including the following five diseases: CD95 (Fas) defect, ALPS type 1a; CD95L (Fas ligand) defect, ALPS type 1b; Caspase 10 defect, ALPS type 2a; Caspase 8 defext, ALPS type 2b; Activaing N-Ras defect, N-Ras ALPS
CAV1 caveolin 1
  • Triglyceride catabolism
  • eNOS activation
  • NOSTRIN mediated eNOS trafficking
  • Thyroxine biosynthesis
  • Basigin interactions
  • Disassembly of the destruction complex and recruitment of AXIN to the membrane
  • VEGFR2 mediated vascular permeability
  • RHOA GTPase cycle
  • Extra-nuclear estrogen signaling
  • RHOB GTPase cycle
  • RHOC GTPase cycle
  • CDC42 GTPase cycle
  • RAC1 GTPase cycle
  • RAC2 GTPase cycle
  • RHOD GTPase cycle
  • RHOQ GTPase cycle
  • RHOH GTPase cycle
  • RHOG GTPase cycle
  • RHOJ GTPase cycle
  • RAC3 GTPase cycle
  • RHOF GTPase cycle
  • FOXO-mediated transcription of cell cycle genes
  • RND3 GTPase cycle
  • RND2 GTPase cycle
  • RND1 GTPase cycle
  • SARS-CoV-1 targets host intracellular signalling and regulatory pathways
  • SARS-CoV-2 targets host intracellular signalling and regulatory pathways
  • Congenital generalized lipodystrophy (CGL)
CAV2 caveolin 2
  • Extra-nuclear estrogen signaling
CBL Cbl proto-oncogene
  • Interleukin-6 signaling
  • Constitutive Signaling by Ligand-Responsive EGFR Cancer Variants
  • Spry regulation of FGF signaling
  • Regulation of KIT signaling
  • EGFR downregulation
  • TGF-beta receptor signaling activates SMADs
  • Constitutive Signaling by EGFRvIII
  • Negative regulation of FGFR1 signaling
  • Negative regulation of FGFR2 signaling
  • Negative regulation of FGFR3 signaling
  • Negative regulation of FGFR4 signaling
  • Negative regulation of MET activity
  • PTK6 Regulates RTKs and Their Effectors AKT1 and DOK1
  • Cargo recognition for clathrin-mediated endocytosis
  • Clathrin-mediated endocytosis
  • InlB-mediated entry of Listeria monocytogenes into host cell
  • InlB-mediated entry of Listeria monocytogenes into host cell
  • Regulation of signaling by CBL
  • Regulation of signaling by CBL
  • Signaling by CSF1 (M-CSF) in myeloid cells
  • Negative regulation of FLT3
  • FLT3 signaling by CBL mutants
  • Noonan syndrome and related disorders, including: Noonan syndrome (NS); Leopard syndrome (LS); Noonan syndrome-like with loose anagen hair (NS/LAH); CBL-mutation associated syndrome (CBL); Neurofibromatosis type 1 (NF1); Neurofibromatosis type 2 (NF2); Neurofibromatosis-Noonan syndrome (NFNS); Legius syndrome; Cardiofaciocutaneous syndrome (CFCS); Costello syndrome (CS)
CBLC Cbl proto-oncogene C
CCDC180 coiled-coil domain containing 180
CCNA1 cyclin A1
  • G0 and Early G1
  • Telomere Extension By Telomerase
  • Cdc20:Phospho-APC/C mediated degradation of Cyclin A
  • Regulation of APC/C activators between G1/S and early anaphase
  • SCF(Skp2)-mediated degradation of p27/p21
  • Senescence-Associated Secretory Phenotype (SASP)
  • DNA Damage/Telomere Stress Induced Senescence
  • Ub-specific processing proteases
  • Processing of DNA double-strand break ends
  • TP53 Regulates Transcription of Genes Involved in G1 Cell Cycle Arrest
  • Regulation of TP53 Activity through Phosphorylation
  • Regulation of TP53 Degradation
  • G2 Phase
  • Orc1 removal from chromatin
  • CDK-mediated phosphorylation and removal of Cdc6
  • G1/S-Specific Transcription
  • Cyclin A/B1/B2 associated events during G2/M transition
  • G2/M DNA replication checkpoint
  • p53-Dependent G1 DNA Damage Response
  • Cyclin A:Cdk2-associated events at S phase entry
  • Chk1/Chk2(Cds1) mediated inactivation of Cyclin B:Cdk1 complex
CD2AP CD2 associated protein
  • Nephrin family interactions
  • Nephrotic syndrome and focal segmental glomerulosclerosis
CD33 CD33 molecule
  • Immunoregulatory interactions between a Lymphoid and a non-Lymphoid cell
  • Neutrophil degranulation
  • Gemtuzumab ozogamicin
  • AVE9633
CD36 CD36 molecule (CD36 blood group)
  • Platelet degranulation
  • Cross-presentation of particulate exogenous antigens (phagosomes)
  • ER-Phagosome pathway
  • MyD88:MAL(TIRAP) cascade initiated on plasma membrane
  • Toll Like Receptor TLR6:TLR2 Cascade
  • PPARA activates gene expression
  • Scavenging by Class B Receptors
  • Scavenging by Class B Receptors
  • Transcriptional regulation of white adipocyte differentiation
  • Intracellular metabolism of fatty acids regulates insulin secretion
  • MyD88 deficiency (TLR2/4)
  • IRAK4 deficiency (TLR2/4)
  • Regulation of TLR by endogenous ligand
  • Interleukin-4 and Interleukin-13 signaling
  • Neutrophil degranulation
  • MLL4 and MLL3 complexes regulate expression of PPARG target genes in adipogenesis and hepatic steatosis
CD44 CD44 molecule (IN blood group)
  • Degradation of the extracellular matrix
  • Cell surface interactions at the vascular wall
  • Hyaluronan metabolism
  • Integrin cell surface interactions
  • Hyaluronan degradation
  • Neutrophil degranulation
  • Interferon gamma signaling
  • Developmental Lineage of Mammary Gland Luminal Epithelial Cells
  • Developmental Lineage of Mammary Gland Myoepithelial Cells
  • Developmental Lineage of Mammary Stem Cells
  • Bivatuzumab
  • Hyaluronic acid
  • Gastric cancer
CD46 CD46 molecule
  • Regulation of Complement cascade
CD47 CD47 molecule
  • Cell surface interactions at the vascular wall
  • Integrin cell surface interactions
  • Signal regulatory protein family interactions
  • Signal regulatory protein family interactions
  • Neutrophil degranulation
CD59 CD59 molecule (CD59 blood group)
  • COPII-mediated vesicle transport
  • Cargo concentration in the ER
  • Neutrophil degranulation
  • COPI-mediated anterograde transport
  • Regulation of Complement cascade
  • Complement regulatory protein defects, including the following six diseases: C1 inhibitor deficiency (hereditary angioedema); C4 binding protein alpha deficiency; C4 binding protein beta deficiency; Factor I deficiency; Decay-accelerating factor (CD55) deficiency; CD59 deficiency

Page 18 out of 32 pages